GU Ventures
GU Ventures, established in 1995 and based in Gothenburg, Sweden, is an accelerator firm dedicated to supporting projects and companies emerging from the University of Gothenburg. Wholly owned by the Swedish state and managed by the university since 1998, GU Ventures collaborates closely with the University of Gothenburg's Research and Innovation Office as well as various local innovation partners. The firm focuses on the commercialization of research and expertise, emphasizing business ideas that demonstrate commercial viability and address customer needs. By nurturing companies primarily in the life sciences and technology sectors, GU Ventures aims to foster successful businesses that can achieve profitability and contribute positively to regional growth. The overarching goal is to generate beneficial knowledge and capital returns to the University of Gothenburg while promoting the application of research to enhance societal well-being through new products and services.
Top Regions
Top Stages
7 past transactions
Thioredoxin Systems
Series A in 2024
Thioredoxin Systems is a biotechnology company focused on developing innovative antibiotic regimens specifically aimed at addressing complicated urinary tract infections. The company has created a patented technology that combines ebselen and silver, which serves multiple purposes as an antiseptic and antibacterial agent. This unique formulation is designed to combat a wide range of multi-drug resistant bacteria, thereby helping to slow the progression of antibiotic resistance. By providing a medicinal product that can be used in various settings, including food production and healthcare, Thioredoxin Systems aims to enhance treatment options and improve patient outcomes in the face of growing antibiotic resistance challenges.
Pretzel Therapeutics
Series A in 2022
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.
Profundus Imaging
Seed Round in 2021
Profundus AB, based in Gothenburg, Sweden, specializes in the research and development of advanced imaging technology for retinal diagnostics. The company is developing a proof-of-concept prototype for a novel fundus camera that utilizes adaptive optics, a technology originally designed for terrestrial telescopes. This innovative approach significantly enhances imaging resolution, offering 7-10 times greater clarity than conventional devices while covering a larger area of the retina. The primary goal of Profundus AB is to create a clinical tool that aids in the diagnosis of retinal diseases by visualizing subclinical changes that may otherwise go unnoticed.
OnDosis
Seed Round in 2020
OnDosis is a Swedish company founded in 2017, focusing on personalized medicine through its innovative dosing technology. The company specializes in delivering flexible and individualized dosing of oral medications, which are formulated as micro units like pellets, granules, mini tablets, or powders. By integrating digital technologies with traditional drug-based treatments, OnDosis aims to enhance disease management and improve patient adherence, particularly for conditions such as ADHD, pain management, and immunosuppression in organ transplant recipients. Their approach addresses the limitations of conventional tablets or capsules, providing greater convenience and improved health outcomes for patients. The technology developed by OnDosis is rooted in research from AstraZeneca and is supported by a network of strategic partners that assist in various core functions, including formulation, device development, and regulatory compliance.
Mimbly
Venture Round in 2020
Mimbly is a manufacturer focused on creating sustainable laundry systems that aim to conserve water while addressing environmental concerns. The company develops innovative solutions designed to recycle water within a washing cycle. Its system connects to washing machines through a water intake valve, allowing it to track, analyze, and purify water for reuse. This technology is particularly beneficial for professional laundry facilities, enabling them to adopt more sustainable practices, reduce water consumption, and minimize microplastic pollution and carbon dioxide emissions. Mimbly's approach reflects a commitment to environmental sustainability and resource conservation.
Recycla
Venture Round in 2018
Recycla is a recycling and waste management company that operates a marketplace platform designed to facilitate environmentally efficient recycling solutions. The platform connects users with quality-assured recycling companies, allowing individuals and organizations to easily find suitable partners for their recycling needs, whether at home, in businesses, or within tenant-owner associations. By providing a database of approved companies, Recycla enables users to efficiently match their specific recycling or waste management requests with the right service providers in their geographic area, promoting sustainable practices and cost-effective solutions in the recycling industry.
Cereno Scientific
Seed Round in 2012
Cereno Scientific AB, established in 2012 and headquartered in Mölndal, Sweden, specializes in developing innovative therapeutics to prevent and treat cardiovascular and rare diseases. The company's primary focus is on epigenetic modulation, specifically through histone deacetylase inhibition (HDACi). Its lead product, CS1, is a phase II dual-acting antithrombotic drug candidate, designed to treat venous thrombosis and prevent stroke in patients with atrial fibrillation. Additionally, Cereno Scientific is exploring the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.